Patient JourneyFAQsClinical StudiesPost-Procedure InstructionsTestimonialsContact

Natural Killer (NK) Cell Therapy in Turkey

A personalized NK cell immunotherapy program in Istanbul — autologous (from the patient) and allogeneic (donor-derived) NK cells, considered only after individual medical evaluation and physician eligibility review.

Istanbul, Turkey
International Patient Support
Personalized Medical Assessment
Hospital & Clinic Coordination
Free Medical ConsultationSend Medical Records for Evaluation

What Is Natural Killer (NK) Cell Therapy?

Natural Killer (NK) cells are lymphocytes of the innate immune system. They develop from the common lymphoid progenitor in the bone marrow and are part of the body's first line of defense — capable of recognizing and acting on abnormal or stressed cells without prior sensitization. NK cells typically express the surface markers CD56 and CD16 and lack the T-cell receptor (TCR).

NK cell therapy uses carefully prepared NK cells — either derived from the patient (autologous) or from a healthy, screened donor (allogeneic) — as part of personalized cellular immunotherapy programs. At Turkey Stem Cell, NK cell therapy in Istanbul is discussed as one of several advanced cellular options after a full medical review.

Turkey Stem Cell coordinates NK cell programs in Istanbul with hospital infrastructure, multidisciplinary physician oversight, defined laboratory protocols, and structured international patient support. Each plan is built around the patient's diagnosis, prior treatments, and clinical context — with transparent discussion of expected benefits, limitations, and risks, and no guaranteed outcomes.

Microscopic visualization of Natural Killer (NK) cells prepared for cellular immunotherapy in Turkey
Turkey Stem Cell physician with Natural Killer cell research visualization in an Istanbul clinical laboratory

How NK Cell Therapy Works — Mechanism, Dosing, and Clinical Context

NK cells eliminate target cells through two main mechanisms studied in cellular immunology. The direct mechanism involves the release of perforin and granzymes that create pores in the target cell surface and trigger programmed cell death (apoptosis). The indirect mechanism uses surface molecules such as FAS and TRAIL death-receptor pathways to signal the target into cell-death programs.

A key feature of NK cells is recognition through Major Histocompatibility Complex class I (MHC I). Healthy cells present MHC I on their surface, which typically protects them from NK action. Abnormal cells — including many tumor cells and virally infected cells — frequently show absent or reduced MHC I, and NK cells are designed to recognize this 'missing-self' signal. This selectivity is the basis for the safety profile of NK cell programs in both autologous and allogeneic settings.

When considered clinically, NK cell dosing is individualized to patient weight, indication, and severity. Cellular immunotherapy literature commonly references dose ranges in the order of one to several million NK cells per kilogram of body weight, with multiple applications spaced over a defined schedule. Administration is most often intravenous; in selected cases the route may be intra-tumoral for accessible solid lesions or intrathecal (into the cerebrospinal fluid) for central-nervous-system indications — only when medically appropriate and under physician oversight.

Scheduling around other treatments matters. NK cell programs at Turkey Stem Cell are coordinated so that infusions do not coincide with cytotoxic chemotherapy or radiotherapy on the same day; a minimum spacing between therapies — typically at least 24 hours, and frequently around a week before or after chemotherapy or radiotherapy — is observed to protect the prepared NK cells and the patient's tolerance. Exact timing is decided by the treating physician based on the patient's regimen and recovery.

Key Aspects of This Therapy

Innate Immune Lymphocytes (CD56+/CD16+)

NK cells express CD56 and CD16, lack the T-cell receptor, and recognize abnormal cells without prior sensitization.

Autologous NK Cells from the Patient

Prepared from the patient's own blood under controlled laboratory conditions and reintroduced under medical supervision.

Allogeneic NK Cells from a Screened Donor

Donor-derived NK cells prepared under strict donor-screening and laboratory protocols, where clinically appropriate.

Controlled NK Cell Laboratory Workflow

Cell preparation follows defined cellular therapy procedures with documentation throughout the workflow.

Physician-Led Eligibility Review in Istanbul

Each case is reviewed individually before any NK cell program in Turkey is considered or proposed.

Personalized NK Cell Treatment Plan

Eligible patients receive a written plan covering proposed approach, schedule, dosing range, and clinical considerations.

Who May Request an Evaluation

This therapy is not appropriate for everyone. The following are examples of clinical contexts where a medical evaluation may be considered:

  • Patients exploring immune-supportive cellular therapy and NK cell programs in Turkey
  • Oncology-related consultations where NK cell immunotherapy may be discussed (case-by-case), including selected hematologic and solid-tumor contexts
  • Patients with selected viral conditions (such as Hepatitis, Herpes Zoster, or Epstein–Barr Virus) where NK-based approaches may be reviewed alongside standard care
  • Patients seeking a second opinion on advanced cellular immunotherapy options
  • International patients requesting coordinated NK cell therapy evaluation in Istanbul

Requesting an evaluation does not guarantee treatment eligibility. Final decisions are made by the treating physician based on the complete medical assessment.

Stem cell laboratory scientist in Istanbul examining NK cell samples under a microscope

Safety & Eligibility

NK cell therapy in Turkey requires careful medical screening. Depending on the case, patients may need complete blood counts, immune profiling, oncology or hematology reports, imaging, infectious-disease screening, medication review, and physician clearance before any cellular therapy program is considered.

For allogeneic (donor-derived) NK programs, donor leukocyte concentrates are screened in line with cellular therapy standards — typically including testing for transmissible infectious diseases. Cells cultured for clinical use are evaluated for purity (NK cell population), absence of unwanted lymphocyte contamination, maturity (CD16+), and cytotoxic activation markers, so that infused cell populations meet defined quality criteria.

Reported adverse effects of NK cell infusions in cellular therapy literature are generally mild to moderate and may include low-grade fever, headache, dizziness, chills, lightheadedness, or nausea — most often resolving within 24 hours and manageable with standard supportive care. Active uncontrolled infections, certain hematologic conditions, advanced organ dysfunction, and some ongoing medications may affect eligibility. NK cell therapy is not a guaranteed cure and outcomes cannot be promised in advance.

No clinical outcome can be guaranteed. All information shared during evaluation is for educational and clinical-planning purposes only and does not replace direct medical advice from your primary care team.

Frequently Asked Questions

NK cell therapy is a cellular immunotherapy approach that uses Natural Killer cells — innate immune lymphocytes that recognize abnormal or stressed cells — prepared either from the patient (autologous) or from a screened donor (allogeneic) and considered as part of a personalized program.

NK cells use a 'missing-self' recognition mechanism based on Major Histocompatibility Complex class I (MHC I). Many abnormal cells present low or absent MHC I, and NK cells are designed to recognize and act on those cells through perforin/granzyme release and death-receptor signaling pathways such as FAS and TRAIL.

NK cells are part of the innate immune system and act without prior sensitization, expressing CD56 and CD16 and lacking the T-cell receptor. T-cell therapies (including CAR T-cell therapy) use adaptive immune cells that recognize antigens through the T-cell receptor and require different laboratory preparation and clinical oversight.

Both options exist. Autologous NK cells come from the patient's own blood; allogeneic NK cells come from a healthy, screened donor. Each option carries distinct laboratory, compatibility, and clinical considerations reviewed case-by-case.

Dosing is individualized to the patient's weight, indication, and severity. Cellular therapy literature commonly references doses in the order of one to several million NK cells per kilogram of body weight, with multiple applications across a defined schedule. The exact plan is decided after physician evaluation.

Administration is most often intravenous. In selected cases, the route may be intra-tumoral for accessible solid lesions or intrathecal (into the cerebrospinal fluid) for central-nervous-system indications — only when medically appropriate and under physician oversight.

Scheduling around cytotoxic chemotherapy and radiotherapy matters. NK cell programs are coordinated so they do not coincide with these treatments on the same day; spacing of at least 24 hours — and commonly around a week before or after chemotherapy or radiotherapy — is typically observed to protect NK cell viability and patient tolerance.

NK cell immunotherapy is studied across a range of indications including selected hematologic conditions (such as leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes), selected solid-tumor contexts (such as breast, lung, colorectal, ovarian, prostate, liver, renal, pancreatic, head and neck, and CNS tumors), and certain viral conditions (Hepatitis, Herpes Zoster, EBV). Discussion is always case-by-case and not a guarantee of treatment or outcome.

Reported adverse effects are generally mild to moderate and may include low-grade fever, headache, dizziness, chills, lightheadedness, or nausea — most often resolving within about 24 hours and manageable with standard supportive care.

Candidacy is determined by physician evaluation. Diagnosis, medical history, current medications, blood and immune profiling results, and prior treatments all inform whether an NK cell program may be appropriate at Turkey Stem Cell.

No. NK cell therapy is not a guaranteed cure. It is one of several advanced cellular immunotherapy approaches that may be discussed as part of personalized care, and outcomes cannot be promised in advance.

Yes. International patients can request medical evaluation and receive coordinated support in Istanbul — including treatment planning, hospital scheduling, hotel arrangements, airport transfers, and translation services.

Submit your diagnosis, recent reports, blood tests, imaging, prior treatments, and current medications. The Turkey Stem Cell medical team will review your case and advise whether an NK cell program may be appropriate.
Turkey Stem Cell doctor consulting an international patient about NK cell therapy options in Istanbul

Request a Personalized Evaluation

Send your diagnosis, recent medical reports, blood tests, imaging, and treatment history. Our medical team will review your case and advise whether this advanced cellular therapy program may be suitable.

Free ConsultationContact on WhatsAppSend Medical Records